Neuromedin U contributes to radiation resistance in colorectal cancer via YAP/TAZ signaling activation

Sim,Myeong-Kyu; Park,Ji-Eun; Kim,So-Ra; Lee,Jeeyong; Kim,Eun Ju; Kim,Younjoo; Shin,Ui Sup; Kim,Hyunggee; Kim,Kwang Seok

doi:10.3892/or.2023.8615

Neuromedin U contributes to radiation resistance in colorectal cancer via YAP/TAZ signaling activation

Authors:
- Myeong-Kyu Sim
- Ji-Eun Park
- So-Ra Kim
- Jeeyong Lee
- Eun Ju Kim
- Younjoo Kim
- Ui Sup Shin
- Hyunggee Kim
- Kwang Seok Kim
View Affiliations

Affiliations: Division of Radiation Biomedical Research, Korea Institute of Radiological and Medical Sciences, Seoul 01812, Republic of Korea, Department of Radiological and Clinical Research, Korea Cancer Center Hospital, Korea Institute of Radiological and Medical Sciences, Seoul 01812, Republic of Korea, Department of Biotechnology, School of Life Sciences and Biotechnology, Korea University, Seoul 02841, Republic of Korea
Published online on: August 16, 2023 https://doi.org/10.3892/or.2023.8615
Article Number: 178

Metrics: Total Views: 0 (Spandidos Publications: | PMC Statistics: )

Metrics: Total PDF Downloads: 0 (Spandidos Publications: | PMC Statistics: )

Cited By (CrossRef): 0 citations Loading Articles...

Abstract

Resistance to radiation therapy remains a treatment obstacle for patients with high‑risk colorectal cancer. Neuromedin U (NMU) has been identified as a potential predictor of the response to radiation therapy by RNA sequencing analysis of colorectal cancer tissues obtained from patients. However, the role of NMU in colorectal cancer remains unknown. In order to investigate role of NMU in colorectal cancer, NMU expression was regulated using small interfering RNA or an NMU‑expression pCMV3 vector, and cell counting, wound‑healing and clonogenic assays were subsequently performed. NMU knockdown decreased colorectal cancer cell proliferation and migration, and sensitized the cells to radiation. Conversely, NMU overexpression increased radiation resistance, proliferation and migration of colorectal cancer cells. Furthermore, by western blotting and nuclear fractionation experiments, NMU knockdown inhibited the nuclear translocation of yes‑associated protein (YAP) and transcriptional co‑activator with PDZ‑binding motif (TAZ), resulting from the phosphorylation of these proteins. By contrast, the nuclear translocation of YAP and TAZ was increased following NMU overexpression in colorectal cancer cells. Recombinant NMU regulated YAP and TAZ activity, and the expression of the YAP and TAZ transcriptional target genes AXL, connective tissue growth factor and cysteine‑rich angiogenic inducer 61 in an NMU receptor 1 activity‑dependent manner. These results suggested that NMU may contribute to the acquisition of radioresistance in colorectal cancer by enhancing the Hippo signaling pathway via YAP and TAZ activation.

View Figures

View References

1	Kim YB and Suh CO: Evolution of radiotherapy: High-precision radiotherapy. J Korean Med Assoc. 51:604–611. 2008. View Article : Google Scholar
2	Gunderson LL and Tepper JE: Clinical radiation oncology. Elsevier Health Sciences; 2015
3	Yang XD, Xu XH, Zhang SY, Wu Y, Xing CG, Ru G, Xu HT and Cao JP: Role of miR-100 in the radioresistance of colorectal cancer cells. Am J Cancer Res. 5:545–559. 2015.PubMed/NCBI
4	Jin H, Gao S, Guo H, Ren S, Ji F, Liu Z and Chen X: Re-sensitization of radiation resistant colorectal cancer cells to radiation through inhibition of AMPK pathway. Oncol Lett. 11:3197–3201. 2016. View Article : Google Scholar : PubMed/NCBI
5	Lee J, Kwon J, Kim D, Park M, Kim K, Bae I, Kim H, Kong J, Kim Y, Shin U and Kim E: Gene expression profiles associated with radio-responsiveness in locally advanced rectal cancer. Biology (Basel). 10:5002021.PubMed/NCBI
6	Austin C, Lo G, Nandha K, Meleagros L and Bloom S: Cloning and characterization of the cDNA encoding the human neuromedin U (NmU) precursor: NmU expression in the human gastrointestinal tract. J Mol Endocrinol. 14:157–169. 1995. View Article : Google Scholar : PubMed/NCBI
7	Howard AD, Wang R, Pong SS, Mellin TN, Strack A, Guan XM, Zeng Z, Williams DL Jr, Feighner SD, Nunes CN, et al: Identification of receptors for neuromedin U and its role in feeding. Nature. 406:70–74. 2000. View Article : Google Scholar : PubMed/NCBI
8	Martinez VG and O'Driscoll L: Neuromedin U: A multifunctional neuropeptide with pleiotropic roles. Clin Chem. 61:471–482. 2015. View Article : Google Scholar : PubMed/NCBI
9	Shan L, Qiao X, Crona JH, Behan J, Wang S, Laz T, Bayne M, Gustafson EL, Monsma FJ Jr and Hedrick JA: Identification of a novel neuromedin U receptor subtype expressed in the central nervous system. J Biol Chem. 275:39482–39486. 2000. View Article : Google Scholar : PubMed/NCBI
10	Brighton PJ, Szekeres PG and Willars GB: Neuromedin U and its receptors: Structure, function, and physiological roles. Pharmacol Rev. 56:231–248. 2004. View Article : Google Scholar : PubMed/NCBI
11	Przygodzka P, Soboska K, Sochacka E and Boncela J: Neuromedin U: A small peptide in the big world of cancer. Cancers (Basel). 11:13122019. View Article : Google Scholar : PubMed/NCBI
12	Li Q, Han L, Ruan S, Shen S, Cao Q, Cai X, Yan Y, Peng B and Hua Y: The prognostic value of neuromedin U in patients with hepatocellular carcinoma. BMC Cancer. 20:952020. View Article : Google Scholar : PubMed/NCBI
13	Pan J, Li S, Chi P, Xu Z, Lu X and Huang Y: Lentivirus-mediated RNA interference targeting WWTR1 in human colorectal cancer cells inhibits cell proliferation in vitro and tumor growth in vivo. Oncol Rep. 28:179–185. 2012.PubMed/NCBI
14	Edgar BA: From cell structure to transcription: Hippo forges a new path. Cell. 124:267–273. 2006. View Article : Google Scholar : PubMed/NCBI
15	Zhao B, Wei X, Li W, Udan RS, Yang Q, Kim J, Xie J, Ikenoue T, Yu J, Li L, et al: Inactivation of YAP oncoprotein by the Hippo pathway is involved in cell contact inhibition and tissue growth control. Genes Dev. 21:2747–2761. 2007. View Article : Google Scholar : PubMed/NCBI
16	Sturbaut M, Bailly F, Coevoet M, Sileo P, Pugniere M, Liberelle M, Magnez R, Thuru X, Chartier-Harlin MC, Melnyk P, et al: Discovery of a cryptic site at the interface 2 of TEAD-towards a new family of YAP/TAZ-TEAD inhibitors. Eur J Med Chem. 226:1138352021. View Article : Google Scholar : PubMed/NCBI
17	Liu C, Huang W and Lei Q: Regulation and function of the TAZ transcription co-activator. Int J Biochem Mol Biol. 2:247–256. 2011.PubMed/NCBI
18	Yu FX, Zhao B, Panupinthu N, Jewell JL, Lian I, Wang LH, Zhao J, Yuan H, Tumaneng K, Li H, et al: Regulation of the Hippo-YAP pathway by G-protein-coupled receptor signaling. Cell. 150:780–791. 2012. View Article : Google Scholar : PubMed/NCBI
19	Kim MH and Kim J: Role of YAP/TAZ transcriptional regulators in resistance to anti-cancer therapies. Cell Mol Life Sci. 74:1457–1474. 2017. View Article : Google Scholar : PubMed/NCBI
20	Livak KJ and Schmittgen TD: Analysis of relative gene expression data using real-time quantitative PCR and the 2(−Delta Delta C(T)) method. Methods. 25:402–408. 2001. View Article : Google Scholar : PubMed/NCBI
21	Fernandez-L A, Squatrito M, Northcott P, Awan A, Holland EC, Taylor MD, Nahlé Z and Kenney AM: Oncogenic YAP promotes radioresistance and genomic instability in medulloblastoma through IGF2-mediated Akt activation. Oncogene. 31:1923–1937. 2012. View Article : Google Scholar : PubMed/NCBI
22	Zhang Y, Wang Y, Zhou D, Wang K, Wang X, Wang X, Jiang Y, Zhao M, Yu R and Zhou X: Radiation-induced YAP activation confers glioma radioresistance via promoting FGF2 transcription and DNA damage repair. Oncogene. 40:4580–4591. 2021. View Article : Google Scholar : PubMed/NCBI
23	Das P, Skibber JM, Rodriguez-Bigas MA, Feig BW, Chang GJ, Wolff RA, Eng C, Krishnan S, Janjan NA and Crane CH: Predictors of tumor response and downstaging in patients who receive preoperative chemoradiation for rectal cancer. Cancer. 109:1750–1755. 2007. View Article : Google Scholar : PubMed/NCBI
24	Kremser C, Trieb T, Rudisch A, Judmaier W and de Vries A: Dynamic T(1) mapping predicts outcome of chemoradiation therapy in primary rectal carcinoma: Sequence implementation and data analysis. J Magn Reson Imaging. 26:662–671. 2007. View Article : Google Scholar : PubMed/NCBI
25	Passiglia F, Bronte G, Castiglia M, Listì A, Calò V, Toia F, Cicero G, Fanale D, Rizzo S, Bazan V and Russo A: Prognostic and predictive biomarkers for targeted therapy in NSCLC: For whom the bell tolls? Expert Opin Biol Ther. 15:1553–1566. 2015. View Article : Google Scholar : PubMed/NCBI
26	Ketterer K, Kong B, Frank D, Giese NA, Bauer A, Hoheisel J, Korc M, Kleeff J, Michalski CW and Friess H: Neuromedin U is overexpressed in pancreatic cancer and increases invasiveness via the hepatocyte growth factor c-Met pathway. Cancer Lett. 277:72–81. 2009. View Article : Google Scholar : PubMed/NCBI
27	Takahashi K, Furukawa C, Takano A, Ishikawa N, Kato T, Hayama S, Suzuki C, Yasui W, Inai K, Sone S, et al: The neuromedin U-growth hormone secretagogue receptor 1b/neurotensin receptor 1 oncogenic signaling pathway as a therapeutic target for lung cancer. Cancer Res. 66:9408–9419. 2006. View Article : Google Scholar : PubMed/NCBI
28	Harten SK, Esteban MA, Shukla D, Ashcroft M and Maxwell PH: Inactivation of the von Hippel-Lindau tumour suppressor gene induces neuromedin U expression in renal cancer cells. Mol Cancer. 10:892011. View Article : Google Scholar : PubMed/NCBI
29	Lin TY, Wu FJ, Chang CL, Li Z and Luo CW: NMU signaling promotes endometrial cancer cell progression by modulating adhesion signaling. Oncotarget. 7:10228–10242. 2016. View Article : Google Scholar : PubMed/NCBI
30	Wu Y, McRoberts K, Berr SS, Frierson HF Jr, Conaway M and Theodorescu D: Neuromedin U is regulated by the metastasis suppressor RhoGDI2 and is a novel promoter of tumor formation, lung metastasis and cancer cachexia. Oncogene. 26:765–773. 2007. View Article : Google Scholar : PubMed/NCBI
31	Martinez VG, Crown J, Porter RK and O'Driscoll L: Neuromedin U alters bioenergetics and expands the cancer stem cell phenotype in HER2-positive breast cancer. Int J Cancer. 140:2771–2784. 2017. View Article : Google Scholar : PubMed/NCBI
32	Yang D, Zhang X, Li Z, Xu F, Tang C and Chen H: Neuromedin U and neurotensin may promote the development of the tumour microenvironment in neuroblastoma. PeerJ. 9:e115122021. View Article : Google Scholar : PubMed/NCBI
33	Shetzline SE, Rallapalli R, Dowd KJ, Zou S, Nakata Y, Swider CR, Kalota A, Choi JK and Gewirtz AM: Neuromedin U: A Myb-regulated autocrine growth factor for human myeloid leukemias. Blood. 104:1833–1840. 2004. View Article : Google Scholar : PubMed/NCBI
34	Przygodzka P, Papiewska-Pajak I, Bogusz H, Kryczka J, Sobierajska K, Kowalska MA and Boncela J: Neuromedin U is upregulated by Snail at early stages of EMT in HT29 colon cancer cells. Biochim Biophys Acta. 1860:2445–2453. 2016. View Article : Google Scholar : PubMed/NCBI
35	Przygodzka P, Sochacka E, Soboska K, Pacholczyk M, Papiewska-Pająk I, Przygodzki T, Płociński P, Ballet S, De Prins A and Boncela J: Neuromedin U induces an invasive phenotype in CRC cells expressing the NMUR2 receptor. J Exp Clin Cancer Res. 40:2832021. View Article : Google Scholar : PubMed/NCBI
36	Besserer-Offroy É, Brouillette RL, Lavenus S, Froehlich U, Brumwell A, Murza A, Longpré JM, Marsault É, Grandbois M, Sarret P and Leduc R: The signaling signature of the neurotensin type 1 receptor with endogenous ligands. Eur J Pharmacol. 805:1–13. 2017. View Article : Google Scholar : PubMed/NCBI
37	Guo Y, Luo J, Zou H, Liu C, Deng L and Li P: Context-dependent transcriptional regulations of YAP/TAZ in cancer. Cancer Lett. 527:164–173. 2022. View Article : Google Scholar : PubMed/NCBI
38	Ciamporcero E, Shen H, Ramakrishnan S, Yu Ku S, Chintala S, Shen L, Adelaiye R, Miles KM, Ullio C, Pizzimenti S, et al: YAP activation protects urothelial cell carcinoma from treatment-induced DNA damage. Oncogene. 35:1541–1553. 2016. View Article : Google Scholar : PubMed/NCBI
39	Tsujiura M, Mazack V, Sudol M, Kaspar HG, Nash J, Carey DJ and Gogoi R: Yes-associated protein (YAP) modulates oncogenic features and radiation sensitivity in endometrial cancer. PLoS One. 9:e1009742014. View Article : Google Scholar : PubMed/NCBI
40	Akervall J, Nandalur S, Zhang J, Qian CN, Goldstein N, Gyllerup P, Gardinger Y, Alm J, Lorenc K, Nilsson K, et al: A novel panel of biomarkers predicts radioresistance in patients with squamous cell carcinoma of the head and neck. Eur J Cancer. 50:570–581. 2014. View Article : Google Scholar : PubMed/NCBI
41	Vigneron AM, Ludwig RL and Vousden KH: Cytoplasmic ASPP1 inhibits apoptosis through the control of YAP. Genes Dev. 24:2430–2439. 2010. View Article : Google Scholar : PubMed/NCBI
42	Lee WY, Kuo CC, Lin BX, Cheng CH, Chen KC and Lin CW: Podocalyxin-like protein 1 regulates TAZ signaling and stemness properties in colon cancer. Int J Mol Sci. 18:20472017. View Article : Google Scholar : PubMed/NCBI